Sign in
Taking peoplePhase 3

Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia

Key facts

Who runs it
Ottawa Heart Institute Research Corporation
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
168 people, planned
Started
8 Apr 2026
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
  • Placebo
Record updated
11 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients who have:
  • Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)
  • age > 18 years
  • given informed consent

Who cannot take part

  • history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix)
  • active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate))
  • Allergies to icosapent ethyl
  • allergies to fish or shellfish
  • unable to give informed consent; Exclusion for CTA portion of the protocol:; Patients with dye allergy will not undergo CTA but will have PET/CT
  • glomerular filtration rate (GFR) <50 ml/min/1.72m2 (excluded from CTA portion)
  • Patients who have:
  • pregnancy (all women of child bearing potential will have a negative BHCG test
  • breastfeeding
  • Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:

Read full original descriptionShow less

What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.

Participants wil:

* take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests

The 2 groups in the trial

  • TreatmentTreatment being tested

    Participants randomized to this arm will receive Vascepa for 6 months.

    Treatment: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

  • PlaceboPlacebo, for comparison

    Participants randomized to this arm will receive placebo for 6 months.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial
Publications
Record updated
11 May 2026